Ph-negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph-positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate

Pediatr Blood Cancer. 2015 Jun;62(6):1070-1. doi: 10.1002/pbc.25428. Epub 2015 Jan 28.

Abstract

Few patients in remission of Ph-positive chronic myelogenous leukemia (CML) develop Ph-negative MDS/AML, usually with clonal cytogenetic abnormalities. Isolated Ph-negative myeloid sarcoma (MS) is presented here as a form of such disorder, different from Ph-positive MS establishing CML relapse in blastic phase. We describe 11-year-old male who developed Ph-negative isolated MS with NPM1 mutation, remaining in complete molecular remission of Ph-positive chronic myeloid leukemia treated with allo-HSCT in first chronic phase and with imatinib and donor lymphocyte infusion in molecular relapse. The possible mechanisms of the tumor formation are reviewed with stress on importance of comprehensive molecular/cytogenetic evaluations.

Keywords: NPM1 mutation; Philadelphia-negative cells; chronic myeloid leukemia; myeloid sarcoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides / therapeutic use*
  • Bone Marrow Transplantation*
  • Child
  • Combined Modality Therapy
  • Fusion Proteins, bcr-abl / analysis
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Mutation*
  • Nuclear Proteins / genetics*
  • Nucleophosmin
  • Philadelphia Chromosome*
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction
  • Sarcoma, Myeloid / genetics*
  • Transplantation, Homologous

Substances

  • Antineoplastic Agents
  • Benzamides
  • NPM1 protein, human
  • Nuclear Proteins
  • Piperazines
  • Pyrimidines
  • Nucleophosmin
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl